NCT00204893View on ClinicalTrials.gov

Evaluation of the Ocular Safety of Calcium Formate in Normal, Healthy Female Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

March 31, 2007

Study Completion Date

March 31, 2007

Conditions
Healthy
Interventions
DRUG

calcium formate

Calcium formate - Each uncoated white tablet will contain 650 mg of calcium formate, (equivalent to 200 mg elemental calcium). Nephro-Tech, LLC, will formulate and provide the calcium formate tablets for the study.

Trial Locations (1)

53792

University of Wisconsin Hospital and Clinics, Madison

All Listed Sponsors
collaborator

Nephro-Tech 1, LLC

UNKNOWN

lead

University of Wisconsin, Madison

OTHER

NCT00204893 - Evaluation of the Ocular Safety of Calcium Formate in Normal, Healthy Female Subjects | Biotech Hunter | Biotech Hunter